Therapeutic response and side effects of repeated radioligand therapy with 177Lu- PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Autor: | Ahmadzadehfar, H., Eppard, E., Kürpig, S., Fimmers, R., Yordanova, A., Schlenkhoff, C.D., Rogenhofer, S., Essler, M. |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: | |
Zdroj: | 62. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie; 20160414-20160415; Münster; DOCV4.6 /20160225/ |
Popis: | Introduction: Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer, making it an optimal target for the treatment of metastasized prostate cancers. Radioligand therapy (RLT) with 177Lu- PSMA-DKFZ-617 (Lu-PSMA) is a novel[for full text, please go to the a.m. URL] 62. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie |
Databáze: | OpenAIRE |
Externí odkaz: |